palladium has been researched along with tris(dibenzylideneacetone)dipalladium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arbiser, JL; Bhandarkar, SS; Bromberg, J; Carrillo, C; Fried, L; Govindarajan, B; Perry, BN; Reddy, K; Selvakumar, P; Sharma, RK; Sohn, A | 1 |
| Arbiser, JL; Bubley, JA; Elsey, J; Pollack, BP; Rao, S; Sasaki, M; Yang, L; Zhu, L | 1 |
2 other study(ies) available for palladium and tris(dibenzylideneacetone)dipalladium
| Article | Year |
|---|---|
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Organometallic Compounds; Palladium | 2008 |
Palladium based nanoparticles for the treatment of advanced melanoma.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Hyaluronic Acid; Male; Melanoma; Metal Nanoparticles; Mice, Nude; Neoplasm Staging; Organometallic Compounds; Palladium; Particle Size; Transcriptome; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |